Propylthiouracil (PTU)

Propylthiouracil is a thiouracil-derived drug used to treat hyperthyroidism (including Graves""" disease) by decreasing the amount of thyroid hormone produced by the thyroid gland. Its notable side effects include a risk of agranulocytosis. PTU inhibits the enzyme thyroperoxidase, which normally acts in thyroid hormone synthesis by oxidizing the anion iodide (I-) to iodine (I0), facilitating iodine"""s addition to tyrosine residues on the hormone precursor thyroglobulin. This is one of the essential steps in the formation of thyroxine (T4). PTU does not inhibit the action of the sodium-dependent iodide transporter located on follicular cells""" basolateral membranes. Inhibition of this step requires competitive inhibitors, such as perchlorate and thiocyanate. PTU also acts by inhibiting the enzyme 5"""-deiodinase (tetraiodothyronine 5""" deiodinase), which converts T4 to the active form T3.